Silmitasertib, also know as CX-4945, is an orally bioavailable small-molecule inhibitor of CK2 with potential antineoplastic activity. CK2 inhibitor CX-4945 selectively binds to and inhibits the enzyme casein kinase II (CK2), which may lead to an inhibition of cellular proliferation. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival.
Synonyms:
5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid;
CX-4945;
Benzo[c]-2,6-naphthyridine-8-carboxylic acid, 5-[(3-chlorophenyl)amino]-;
5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid;
Properties:
Density: 1.491 g/cm3
Boiling Point: 568.45ºC at 760 mmHg
Flash Point: 297.588ºC
Casein Kinase Inhibitor Related Prodcuts:
LY294002; LY364947; IWP-2; TTP 22; SR-3029